细胞焦亡在心肌缺血再灌注损伤中的研究进展  

Research progress of cell pyroptosis in myocardial ischemia-reperfusion injury

作　　者：周刚 吴辉 刘滴 李云曌 张栋 ZHOU Gang;WU Hui;LIU Di;LI Yunzhao;ZHANG Dong(Institute of Cardiovascular Disease,Three Gorges University&Department of Cardiology,Yichang Central People s Hospital&Hubei Provincial Clinical Research Center for Ischemic Cardiovascular Disease,Yichang,Hubei 443003,China)

机构地区：[1]三峡大学心血管病研究所,宜昌市中心人民医院心血管内科,湖北省缺血性心血管疾病临床医学研究中心,湖北省宜昌市443003

出　　处：《中国动脉硬化杂志》2022年第6期524-528,共5页Chinese Journal of Arteriosclerosis

基　　金：国家自然科学基金项目(81600234);湖北省卫生健康科研基金项目(WJ2021M064)。

摘　　要：心肌缺血再灌注损伤(MIRI)是导致心肌梗死患者经积极血运重建后仍发生较高死亡率的主要原因之一,寻找减轻MIRI的有效干预靶点并探索其保护机制具有重要的意义。细胞焦亡是细胞坏死和凋亡之外的一种炎性程序性细胞死亡方式。近年来,研究发现细胞焦亡与MIRI的发生发展具有密切联系。本文对细胞焦亡及其在MIRI中的作用机制进行综述,并讨论小分子药物、天然药物以及临床常用药物影响细胞焦亡并应用于MIRI防治的研究新进展。Myocardial ischemia-reperfusion injury(MIRI)is one of the main causes of high mortality in patients with myocardial infarction after active revascularization.It is of great significance to find effective intervention targets to alleviate MIRI and explore its protective mechanism.Cell pyroptosis is a form of inflammatory programmed cell death in addition to cell necrosis and apoptosis.In recent years,studies have found that pyroptosis is closely related to the occurrence and development of MIRI.This article reviews the pyroptosis and its mechanism of action in MIRI,and discusses the new research progress of small-molecule drugs,natural drugs and commonly used clinical drugs which affect cell pyroptosis and applied in the prevention and treatment of MIRI.

关 键 词：细胞焦亡 心肌缺血再灌注损伤 Nod样受体蛋白3 半胱氨酸天冬氨酸特异性蛋白酶1 

分 类 号：R541[医药卫生—心血管疾病]